Denali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS)
Retrieved on:
Wednesday, October 6, 2021
Goal, Neurodegeneration, Review, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, AD, Communication, RIPK1, Safety, SEC, Neuron, Food, Biomarker, PTV, Pathology, Traffic barrier, Central nervous system, Adult, Prisoner transport vehicle, MS, Frontotemporal dementia, VWM, CNS, Mouse, Clinical trial, Therapy, Inflammation, White matter, NASDAQ, U.S. Securities and Exchange Commission, FDA, Fast Track, Blood, EIF2B, ISR, Marketing, Human, Lists of diseases, Risk, Brain, Forward-looking statement, FTD, Multiple sclerosis, GLOBE, Pharmacokinetics, PK, Security (finance), Amyotrophic lateral sclerosis, Patient, Preclinical development, COVID-19, PD, ALS, Sanofi, BBB, Pharmaceutical industry, Communications satellite, Medical device
DNL343 and SAR443820 are designed to modulate distinct biological pathways implicated in ALS, including the integrated stress response and inflammation, respectively.
Key Points:
- DNL343 and SAR443820 are designed to modulate distinct biological pathways implicated in ALS, including the integrated stress response and inflammation, respectively.
- Denali presented positive results from a Phase 1 study in healthy volunteers (n=95) in which safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses of DNL343 were evaluated.
- Denali and Sanofi entered into a broad collaboration in October 2018 for the global development and commercialization of RIPK1 inhibitors.
- The forward-looking statements in this press release are based on information available to Denali as of the date hereof.